

MNKD Products & Pipeline

Cardiometabolic

Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
Afrezza® (insulin human) Inhalation Powder	T1DM / T2DM (adults)	Marketed				
	T1DM / T2DM (pediatrics)	PDUFA: Q2 2026				
V-Go® All-in-One Insulin Delivery Patch	T1DM / T2DM (adults)	Marketed				
FUROSCIX® (furosemide injection) (marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)	Edema from CHF / CKD (adults)	Marketed (adults); Pediatrics (PDUFA: Q4 2025)				
FUROSCIX ReadyFlow™ Autoinjector	Edema from CHF / CKD	PDUFA: July 26, 2026				
Bumetanide DPI (MNKD-701)	Edema from CHF / CKD	Pre-Clinical				
Tyvaso DPI® (treprostinil) Inhalation Powder (marketed by United Therapeutics)	PAH / PH-ILD	Marketed				
Nintedanib DPI (MNKD-201)	IPF	Phase 2 (Inflo-2 study)				
Clofazimine DPI (MNKD-102)	NTM	Pre-Clinical				
Partner Program with United Therapeutics (MNKD-1501)	UNDISCLOSED	STAGE UNDISCLOSED				